Research Article
Results of a Randomized, Double-Blinded, Placebo-Controlled, Phase 2.5 Study of Saracatinib (AZD0530), in Patients with Recurrent Osteosarcoma Localized to the Lung
Figure 2
Progression-free survival. Intent-to-treat analysis demonstrated a median PFS of 19.4 months in the treatment group and 8.6 months in the control group.